Akums Drugs and Pharmaceuticals Q4 FY26 Results: PAT of Rs 87.40 crore Contract Manufacturing – Pharma CDMO

Akums Drugs and Pharmaceuticals Q4 results were announced on May 14, 2026, at the company’s board meeting. the company Reported profit was Rs 87.40 crore. India’s largest contract pharmaceutical manufacturer provides formulation development and manufacturing services to domestic and multinational pharmaceutical companies. Investors tracking the company will find complete financial data, analysis, and FY27 outlook in this article.

Click Here – Get Free Investment Predictions

Akums Drugs and Pharmaceuticals Q4 FY26 Key Financial Highlights

Metric	Q4 FY26	Comparison
PAT (Net Profit)	Rs 87.40 crore	Q4 FY25 / Reference
Ticker	AKUMS	Sector: Contract Manufacturing – Pharma CDMO

Screen the best stocks on the Univest Screener.

Akums Drugs and Pharmaceuticals Performance Analysis

The company results reflect the company’s operational performance during the January to March 2026 quarter. the company Reported profit was Rs 87.40 crore. India’s largest contract pharmaceutical manufacturer provides formulation development and manufacturing services to dome Investors and analysts monitoring the company results will focus on FY27 revenue guidance, margin trajectory, and management commentary on business outlook.

The company performance positions the company for FY27. Track the company analyst ratings and live stock price on the Univest Screener for real-time investment insights.

Akums Drugs and Pharmaceuticals FY27 Outlook

Post Akums, investor focus for FY27 will be on revenue growth momentum, margin expansion, new order wins, and sector-specific tailwinds in the Contract Manufacturing – Pharma CDMO space. The Akums results demonstrate the company’s execution capabilities. Track Akums updates on the Univest Screener for analyst views and FY27 earnings estimates.

Download the Univest iOS App or the Univest Android App to track live price and Q4 FY26 earnings updates.

Frequently Asked Questions on Akums Drugs and Pharmaceuticals Q4 FY26 Results

What is it PAT?

Ans. Akums profit after tax was Rs 87.40 crore.

When did Akums Drugs and Pharmaceuticals announce Q4 FY26 results?

Ans. the company results were announced on May 14, 2026, at the company’s board meeting and filed with BSE and NSE.

What is the FY27 outlook for Akums Drugs and Pharmaceuticals?

Ans. Post the company results, investors will track FY27 guidance and growth strategies in the Contract Manufacturing – Pharma CDMO sector. Track live updates on the Univest Screener.

Where can I track the company live data?

Ans. Track the company live stock price, analyst ratings, and earnings updates on the Univest Screener for real-time investment data.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered advisor before making any investment decision.